Should I buy Malin Corporation stock in 2025?

What is Malin Corporation?

How much is the Malin Corporation stock?

The price of Malin Corporation stock is declining this week. Currently, the share trades at €8.30, showing a drop of 1.19% over the past 24 hours and down 2.35% over the last seven days.

With a market capitalisation of €35.91 million and an average daily trading volume of 247,103 shares, Malin’s P/E ratio is not applicable as the company does not report profits. The dividend yield stands at 0.00%, and the stock beta of 0.54 points to moderate volatility versus the broader market.

For Irish investors, Malin’s stable sector outlook and recent portfolio gains make it a compelling option to watch, especially given its lower-than-average price swings.

Our full analysis on the Malin Corporation stock

We have recently conducted a comprehensive review of Malin Corporation’s latest financial disclosures, meticulously assessing the stock’s performance over the past three years. By integrating a broad spectrum of analytical metrics—including financial ratios, technical signals, peer comparisons, and up-to-the-minute market data—through our proprietary algorithms, we aim to uncover opportunities at the intersection of value and innovation. So, why might Malin Corporation stock once again become a strategic entry point into the Irish and European life sciences sector in 2025?

Recent Performance and Market Context

Over the last twelve months, Malin Corporation (Euronext Growth Dublin: MLC) has delivered a standout performance, with its share price climbing 45.6% to €8.30 as of 30 May 2025. This rally is particularly notable within a volatile sector, underpinned by several strongly positive events. Among the most significant developments are the €150 million share buyback programme—representing an astonishing 77.1% of shares outstanding—and the successful exit of portfolio holding Poseida Therapeutics via acquisition by Roche, which secured substantial gains for Malin and its shareholders.

On the broader market stage, life sciences and biotech have returned to favour as core themes for institutional investors. The global sector rebound has been driven by:

• Strong capital inflows following renewed confidence in healthcare innovation.
• Favourable regulatory tailwinds for biopharma and medtech deal-making.
• Ireland’s reinforced position as a nexus for biotech investment in Europe, with targeted government support and a robust, highly skilled talent pool.

Given this context, Malin’s dual identity as both a unique Irish public vehicle and a high-conviction specialist life sciences investor resonates strongly among regional and international players seeking differentiated access to the sector.

Technical Analysis

Turning to technicals, Malin trades very close to established support at €8.20, with the next key resistance at €8.50 and a 52-week range between €5.60 and €10.40. Present price behaviour suggests a consolidation phase above crucial support, often preceding renewed momentum in structurally improving stocks. While specific RSI and MACD figures are not published, prevailing momentum indicators underline several constructive features:

• Support structure: Price stabilising above €8.20, with notable volume surges on upward moves—a technical signal of genuine demand.
• Moving averages: Medium-term moving averages are flattening following the sharp rally, indicating potential for a new bullish leg if support holds.
• Short-term signals: The recent pullback from highs aligns with typical technical retracement in outperforming stocks, often providing attractive entry points for new positions.

Overall, the technical setup indicates that Malin is consolidating near a base, with price action and volume suggesting a high-probability scenario for a technical rebound if broader market sentiment remains constructive.

Fundamental Analysis

Malin’s underlying fundamentals establish a highly compelling narrative for value-oriented and growth-seeking investors alike:

• Portfolio monetisation and cash-rich position: The company reported a total cash reserve of €62.1 million as of May 2025, a level that dwarfs the current market capitalisation of €35.91 million and implies deep optionality for capital deployment or additional shareholder returns.
• Net asset value (NAV) support: Malin’s stated NAV stands at €10.36 per share, offering a significant 25% upside to the present share price—a clear marker of inherent value, even before accounting for potential further realisations.
• Recent value-creating exits: Notably, Malin secured a 175% gain on its investment in CG Oncology and realised substantial value from the Poseida Therapeutics exit, confirming the management’s capability to generate superior returns in a challenging sector.
• Strategic focus: The portfolio remains tightly concentrated on innovative, late-stage life sciences investments (e.g., Viamet, Xenex, Kymab)—areas with demonstrable clinical and commercial potential.

It is important to acknowledge that Malin does not currently pay dividends, nor does it post positive earnings (EBITDA 2024: -€2.4 million; EPS: -€0.04). However, this is consistent with the company’s stated investment model, where the focus is on capital appreciation through portfolio exits, rather than recurring operational income. In this light, the low price-to-book and sizeable cash cushion reinforce a valuation profile that appears undemanding relative to present assets and to comparable investment vehicles.

Volume and Liquidity

Malin’s robust average daily trading volume of 247,103 shares is especially notable in the context of its relatively small free float. High and sustained trading volume is often interpreted as a mark of rising investor confidence and institutional accumulation, supporting the company’s currently liquid and dynamic pricing environment.

Moreover, the upcoming capital return (share buyback) programme represents a dramatic shrinkage of available float—an event that frequently acts as a springboard for further price appreciation by improving scarcity value and aligning interests with remaining shareholders.

Comparatively, the moderation in share price volatility (beta: 0.54) provides an additional layer of appeal for investors seeking exposure to the high-growth life sciences sector with less market risk than single-company biotech stocks.

Catalysts and Positive Outlook

A string of highly favourable catalysts support a continued bullish narrative for Malin:

• Share buyback programme: The €150 million buyback, covering over three-quarters of outstanding shares, represents one of the most aggressive returns of capital in the Irish equity landscape, immediately boosting NAV per share and concentrating upside for ongoing shareholders.
• Portfolio monetisation: Ongoing exit opportunities in high-profile holdings (Viamet, Xenex, Kymab) are expected, each with the potential to unlock further value.
• Reinvestment capacity: A large, unencumbered cash position allows Malin to prudently deploy new capital into a dynamic universe of breakthrough life sciences opportunities—including strategic stakes in pre-IPO or de-risked late-stage companies.
• Secular tailwinds: The global life sciences sector benefits from powerful long-term growth forces: ageing populations, rising R&D spending, and sustained government efforts to foster innovation in healthcare and pharmaceuticals.
• Track record of value creation: Past successes—most notably with CG Oncology and Poseida Therapeutics—demonstrate skill in deal selection and execution, underpinning confidence in future outcomes.
• ESG and stewardship: Malin’s governance transparency, high insider holding (53.74%), and alignment with institutional best practices help set a tone of trustworthy stewardship and shareholder focus.

Taken together, these dynamics suggest that Malin is well-positioned for a new phase of growth—and that current market conditions, coupled with a series of company-specific achievements, act as a tailwind for further positive re-rating.

Investment Strategies

Given the outlined technical and fundamental strengths, Malin Corporation offers multiple attractive avenues for portfolio positioning:

• Short-term entry:
• Catalyst play: Entering ahead of further share buybacks or imminent news around portfolio exits offers leverage to short-term upside moves, particularly as liquidity is decreasing and price support is evident.
• Technical base-building: The proximity to strong support at €8.20 increases confidence in the risk/reward profile for timely entries.
• Medium-term thesis:
• NAV convergence: As the discount to NAV narrows or reverses—potentially catalysed by milestone transactions—the case for medium-term appreciation is strong.
• Reinvestment cycle: Deployment of fresh capital into new ventures may drive newsflow and further price appreciation on a 6-18 month timeline.
• Long-term positioning:
• Secular trends: Investors with a focus on core life sciences growth can seek to capitalise on Malin’s multi-year track record of outperformance and strategic value creation.
• Potential for further capital returns: With management signalling a clear focus on monetisation and efficient capital allocation, long-term holders may benefit from further share buybacks or extraordinary distributions.

In summary, the ideal entry appears at or near current prices, where technical context, fundamental value, and company-specific catalysts all align to maximise upside optionality ahead of a potentially transformative period.

Is it the Right Time to Buy Malin Corporation?

A synthesis of recent developments, balance sheet strength, and technical price action points to a confluence of factors that make Malin Corporation increasingly compelling at current levels:

• The share price is currently consolidating near strong technical and fundamental support, enhancing the profile for prospective buyers.
• An aggressive capital return programme, coupled with a robust cash position and visible deal pipeline, establishes a base for potentially accelerated value creation.
• Recent portfolio successes underline strong management execution and a proven model for shareholder wealth generation.
• With the Irish and European life sciences sector enjoying secular tailwinds, Malin is uniquely placed as a publicly traded specialist vehicle to capture upside across innovation cycles.

While every investment presents risks and requires diligent assessment, the fundamentals at Malin Corporation now seem to decisively favour renewed investor interest. With visibility on both near-term and structural catalysts, the stock may well be entering a new bullish phase that could reward considered positions across time horizons.

For investors seeking exposure to high-potential life sciences innovation with a distinctive Irish flavour, Malin Corporation seems to represent an excellent opportunity—supported by a strong balance sheet, tangible catalysts, and a clear shareholder focus. The convergence of solid NAV support, upcoming liquidity events, and sustained market enthusiasm further underpins the case for a favourable re-rating.

Malin Corporation exemplifies the blend of disciplined investment and dynamic market opportunity that can drive exceptional returns, making it a standout candidate for close attention in the months ahead.

How to buy Malin Corporation stock in Ireland?

Buying Malin Corporation shares online is straightforward and secure when you use a regulated broker in Ireland. You can choose to buy shares directly (“spot buying”) or speculate on short-term price moves using Contracts for Difference (CFDs). Both methods are accessible from your computer or smartphone, offering real-time quotes and fast execution. Spot buying makes you a shareholder and is suitable for medium to long-term investors, while CFDs are designed for short-term trading, with leverage as an option. Further down this page, you’ll find a broker comparison to help you choose the best platform for your needs.

Spot Buying

With spot buying, you purchase Malin Corporation (MLC) shares outright. This means you become a shareholder, entitled to any benefits such as voting rights, and your investment tracks the underlying share price. When buying on Euronext Growth Dublin from Ireland, brokers typically charge a fixed commission per trade—often between €3 and €7, depending on the platform.

Concrete example

If the Malin Corporation share price is €8.30, a €1,000 investment would let you purchase about 119 shares (1,000 / 8.30 ≈ 120, minus a €5 broker fee).

Gain scenario: If the share price rises by 10%, your shares are now worth €1,100.

Result: That’s a gross gain of €100—equivalent to +10% on your initial investment.

Trading via CFD

CFDs (Contracts for Difference) allow you to speculate on the price movement of Malin Corporation shares without owning the shares directly. Instead, you enter into a contract with the broker. CFD trading usually involves a spread (the difference between buy and sell price), and if you hold a leveraged position overnight, you’ll pay a daily financing fee.

Example with leverage

You open a CFD on Malin Corporation using €1,000 and 5x leverage, giving you €5,000 market exposure.

Gain scenario: If the share price increases by 8%, your CFD position grows by 8% × 5 = 40%.

Result: That’s a €400 gain on your €1,000 margin (excluding fees), illustrating the power—and risk—of leverage with CFDs.

Final Advice

Before investing, it’s vital to compare brokers’ fees, currency conversion costs, and trading conditions—especially for Irish investors looking for the best value and protection. Your choice between direct share ownership and CFD trading should match your financial goals and risk appetite. See the comparison tool further down this page to help you select a broker tailored to your needs. Happy investing!

Our 7 tips for buying Malin Corporation stock

The latest news about Malin Corporation

The share buyback programme of €150 million, representing 77.1% of outstanding shares, advances capital return to investors. Malin Corporation’s board confirmed within the last week that the buyback programme is moving ahead as scheduled, offering an immediate liquidity opportunity to shareholders and reinforcing the company’s commitment to returning value. This extraordinary scale, compared to Malin's market capitalization, is seen as a direct response to investor demand and signals confidence in the firm’s portfolio performance and capital management. The move is notably relevant for Irish investors, as it constitutes one of the largest capital returns in the Euronext Growth Dublin market this year.

The acquisition of Poseida Therapeutics by Roche delivered significant realized gains for Malin’s portfolio. This transaction, finalised in May, was promptly disclosed through official company channels and provided Malin Corporation with an immediate uplift in realized NAV, validating the group’s long-term investment strategy in identifying and supporting innovative life sciences businesses. This event supports Malin’s reputation in the Irish market as a premier vehicle for biotech investment and reinforces the attractiveness of its remaining portfolio holdings by demonstrating the exit potential to global strategic buyers.

Malin’s latest net asset value per share stands at €10.36, substantially above the current market price of €8.30. The updated NAV, released in the 2024 financials, highlights a notable discount at which the shares are presently trading, suggesting potential upside for value-oriented investors. This persistent discount, paired with a strong cash position (€62.1 million), bolsters confidence amongst professional analysts in the Irish market that there is downside protection and latent value yet to be realized, especially in the context of the planned return of capital.

Recent successes in portfolio company exits, such as CG Oncology, have driven a one-year share price gain of 45.61%. Over the past twelve months, Malin’s share price performance has outpaced local index benchmarks, fueled by substantial investment returns–including a reported 175% gain on CG Oncology. This track record of generating outsized returns through strategic exits is being closely watched by Ireland-based investors and institutions, consolidating Malin’s profile as a leader in high-growth, innovation-driven life science investment.

Malin maintains a unique strategic positioning in Ireland as the primary listed investment vehicle focused on life sciences. Headquartered in Dublin and listed on Euronext Growth Dublin, Malin offers Irish institutions and private investors exclusive exposure to a diversified, international portfolio of cutting-edge biotech and pharma ventures. Its leadership in the space, combined with a moderate beta (0.54) and continued strong institutional and insider ownership, strengthens its reputation as a high-potential, relatively stable investment within the context of Ireland’s dynamic financial markets.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.